Cargando…

A single-dose, randomized crossover study in healthy Chinese subjects to evaluate pharmacokinetics and bioequivalence of two capsules of calcium dobesilate 0.5 g under fasting and fed conditions

OBJECTIVES: To compare the rate and extent of absorption of a launched generic calcium dobesilate capsule versus the branded reference formulation under fasting and fed conditions in healthy Chinese subjects, and to assess their bioequivalence and tolerability. METHODS: This single-dose, open-label,...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yanmei, Cheng, Jie, Liang, Liyu, Qian, Weigang, Ou, Meixian, Zhang, Mengqi, Wang, Yijun, Wang, Yan, Peng, Ka, Jia, Jingying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121042/
https://www.ncbi.nlm.nih.gov/pubmed/37083730
http://dx.doi.org/10.1371/journal.pone.0284576
_version_ 1785029299067158528
author Liu, Yanmei
Cheng, Jie
Liang, Liyu
Qian, Weigang
Ou, Meixian
Zhang, Mengqi
Wang, Yijun
Wang, Yan
Peng, Ka
Jia, Jingying
author_facet Liu, Yanmei
Cheng, Jie
Liang, Liyu
Qian, Weigang
Ou, Meixian
Zhang, Mengqi
Wang, Yijun
Wang, Yan
Peng, Ka
Jia, Jingying
author_sort Liu, Yanmei
collection PubMed
description OBJECTIVES: To compare the rate and extent of absorption of a launched generic calcium dobesilate capsule versus the branded reference formulation under fasting and fed conditions in healthy Chinese subjects, and to assess their bioequivalence and tolerability. METHODS: This single-dose, open-label, randomized-sequence, 2-period crossover bioequivalence study was conducted on healthy Chinese volunteers aged 18 to 45 years. Subjects received a single 0.5 g dose of calcium dobesilate capsule under fasting or fed conditions, with a 3-day washout period between doses of the test (T) and reference (R) formulations. Blood samples were collected before and up to 24 hours after administration. The plasma concentration of calcium dobesilate was determined by a validated Liquid chromatography-tandem mass spectrometry method. Non-compartmental analysis was applied to identify the pharmacokinetic (PK) properties. The primary PK parameters including the maximal plasma concentration (C(max)), the area under the plasma concentration-time curve (AUC(0-t)), and the AUC extrapolated to infinity (AUC(0-inf)) were used for bioequivalence evaluation. RESULTS: The mean of PK parameters for T and R capsules under fasting (fed) condition were: C(max), 13.57 (6.71) and 12.59 (7.25) μg/mL; AUC(0-t), 97.32 (79.74) and 96.97 (80.71) h*μg/mL; AUC(0-inf), 101.68 (88.01) and 101.64 (87.81) h*μg/mL. The 90% confidence intervals (CIs) of GMRs under fasting (fed) condition were: C(max), 97.91%-116.62% (88.63%-96.53%); AUC(0-t), 97.15%-104.00% (96.58%-101.39%); and AUC(0-inf), 97.19%-102.89% (98.67%-103.99%). These 90% CIs were all within the bioequivalence range of 80%-125%. All adverse events were mild. CONCLUSION: In this study, the T calcium dobesilate 0.5 g capsule was bioequivalent to the reference product under both fasting and fed conditions. Taking food would slow down its rate and reduce its amount of absorption. Both formulations were generally well tolerated.
format Online
Article
Text
id pubmed-10121042
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-101210422023-04-22 A single-dose, randomized crossover study in healthy Chinese subjects to evaluate pharmacokinetics and bioequivalence of two capsules of calcium dobesilate 0.5 g under fasting and fed conditions Liu, Yanmei Cheng, Jie Liang, Liyu Qian, Weigang Ou, Meixian Zhang, Mengqi Wang, Yijun Wang, Yan Peng, Ka Jia, Jingying PLoS One Research Article OBJECTIVES: To compare the rate and extent of absorption of a launched generic calcium dobesilate capsule versus the branded reference formulation under fasting and fed conditions in healthy Chinese subjects, and to assess their bioequivalence and tolerability. METHODS: This single-dose, open-label, randomized-sequence, 2-period crossover bioequivalence study was conducted on healthy Chinese volunteers aged 18 to 45 years. Subjects received a single 0.5 g dose of calcium dobesilate capsule under fasting or fed conditions, with a 3-day washout period between doses of the test (T) and reference (R) formulations. Blood samples were collected before and up to 24 hours after administration. The plasma concentration of calcium dobesilate was determined by a validated Liquid chromatography-tandem mass spectrometry method. Non-compartmental analysis was applied to identify the pharmacokinetic (PK) properties. The primary PK parameters including the maximal plasma concentration (C(max)), the area under the plasma concentration-time curve (AUC(0-t)), and the AUC extrapolated to infinity (AUC(0-inf)) were used for bioequivalence evaluation. RESULTS: The mean of PK parameters for T and R capsules under fasting (fed) condition were: C(max), 13.57 (6.71) and 12.59 (7.25) μg/mL; AUC(0-t), 97.32 (79.74) and 96.97 (80.71) h*μg/mL; AUC(0-inf), 101.68 (88.01) and 101.64 (87.81) h*μg/mL. The 90% confidence intervals (CIs) of GMRs under fasting (fed) condition were: C(max), 97.91%-116.62% (88.63%-96.53%); AUC(0-t), 97.15%-104.00% (96.58%-101.39%); and AUC(0-inf), 97.19%-102.89% (98.67%-103.99%). These 90% CIs were all within the bioequivalence range of 80%-125%. All adverse events were mild. CONCLUSION: In this study, the T calcium dobesilate 0.5 g capsule was bioequivalent to the reference product under both fasting and fed conditions. Taking food would slow down its rate and reduce its amount of absorption. Both formulations were generally well tolerated. Public Library of Science 2023-04-21 /pmc/articles/PMC10121042/ /pubmed/37083730 http://dx.doi.org/10.1371/journal.pone.0284576 Text en © 2023 Liu et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Liu, Yanmei
Cheng, Jie
Liang, Liyu
Qian, Weigang
Ou, Meixian
Zhang, Mengqi
Wang, Yijun
Wang, Yan
Peng, Ka
Jia, Jingying
A single-dose, randomized crossover study in healthy Chinese subjects to evaluate pharmacokinetics and bioequivalence of two capsules of calcium dobesilate 0.5 g under fasting and fed conditions
title A single-dose, randomized crossover study in healthy Chinese subjects to evaluate pharmacokinetics and bioequivalence of two capsules of calcium dobesilate 0.5 g under fasting and fed conditions
title_full A single-dose, randomized crossover study in healthy Chinese subjects to evaluate pharmacokinetics and bioequivalence of two capsules of calcium dobesilate 0.5 g under fasting and fed conditions
title_fullStr A single-dose, randomized crossover study in healthy Chinese subjects to evaluate pharmacokinetics and bioequivalence of two capsules of calcium dobesilate 0.5 g under fasting and fed conditions
title_full_unstemmed A single-dose, randomized crossover study in healthy Chinese subjects to evaluate pharmacokinetics and bioequivalence of two capsules of calcium dobesilate 0.5 g under fasting and fed conditions
title_short A single-dose, randomized crossover study in healthy Chinese subjects to evaluate pharmacokinetics and bioequivalence of two capsules of calcium dobesilate 0.5 g under fasting and fed conditions
title_sort single-dose, randomized crossover study in healthy chinese subjects to evaluate pharmacokinetics and bioequivalence of two capsules of calcium dobesilate 0.5 g under fasting and fed conditions
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121042/
https://www.ncbi.nlm.nih.gov/pubmed/37083730
http://dx.doi.org/10.1371/journal.pone.0284576
work_keys_str_mv AT liuyanmei asingledoserandomizedcrossoverstudyinhealthychinesesubjectstoevaluatepharmacokineticsandbioequivalenceoftwocapsulesofcalciumdobesilate05gunderfastingandfedconditions
AT chengjie asingledoserandomizedcrossoverstudyinhealthychinesesubjectstoevaluatepharmacokineticsandbioequivalenceoftwocapsulesofcalciumdobesilate05gunderfastingandfedconditions
AT liangliyu asingledoserandomizedcrossoverstudyinhealthychinesesubjectstoevaluatepharmacokineticsandbioequivalenceoftwocapsulesofcalciumdobesilate05gunderfastingandfedconditions
AT qianweigang asingledoserandomizedcrossoverstudyinhealthychinesesubjectstoevaluatepharmacokineticsandbioequivalenceoftwocapsulesofcalciumdobesilate05gunderfastingandfedconditions
AT oumeixian asingledoserandomizedcrossoverstudyinhealthychinesesubjectstoevaluatepharmacokineticsandbioequivalenceoftwocapsulesofcalciumdobesilate05gunderfastingandfedconditions
AT zhangmengqi asingledoserandomizedcrossoverstudyinhealthychinesesubjectstoevaluatepharmacokineticsandbioequivalenceoftwocapsulesofcalciumdobesilate05gunderfastingandfedconditions
AT wangyijun asingledoserandomizedcrossoverstudyinhealthychinesesubjectstoevaluatepharmacokineticsandbioequivalenceoftwocapsulesofcalciumdobesilate05gunderfastingandfedconditions
AT wangyan asingledoserandomizedcrossoverstudyinhealthychinesesubjectstoevaluatepharmacokineticsandbioequivalenceoftwocapsulesofcalciumdobesilate05gunderfastingandfedconditions
AT pengka asingledoserandomizedcrossoverstudyinhealthychinesesubjectstoevaluatepharmacokineticsandbioequivalenceoftwocapsulesofcalciumdobesilate05gunderfastingandfedconditions
AT jiajingying asingledoserandomizedcrossoverstudyinhealthychinesesubjectstoevaluatepharmacokineticsandbioequivalenceoftwocapsulesofcalciumdobesilate05gunderfastingandfedconditions
AT liuyanmei singledoserandomizedcrossoverstudyinhealthychinesesubjectstoevaluatepharmacokineticsandbioequivalenceoftwocapsulesofcalciumdobesilate05gunderfastingandfedconditions
AT chengjie singledoserandomizedcrossoverstudyinhealthychinesesubjectstoevaluatepharmacokineticsandbioequivalenceoftwocapsulesofcalciumdobesilate05gunderfastingandfedconditions
AT liangliyu singledoserandomizedcrossoverstudyinhealthychinesesubjectstoevaluatepharmacokineticsandbioequivalenceoftwocapsulesofcalciumdobesilate05gunderfastingandfedconditions
AT qianweigang singledoserandomizedcrossoverstudyinhealthychinesesubjectstoevaluatepharmacokineticsandbioequivalenceoftwocapsulesofcalciumdobesilate05gunderfastingandfedconditions
AT oumeixian singledoserandomizedcrossoverstudyinhealthychinesesubjectstoevaluatepharmacokineticsandbioequivalenceoftwocapsulesofcalciumdobesilate05gunderfastingandfedconditions
AT zhangmengqi singledoserandomizedcrossoverstudyinhealthychinesesubjectstoevaluatepharmacokineticsandbioequivalenceoftwocapsulesofcalciumdobesilate05gunderfastingandfedconditions
AT wangyijun singledoserandomizedcrossoverstudyinhealthychinesesubjectstoevaluatepharmacokineticsandbioequivalenceoftwocapsulesofcalciumdobesilate05gunderfastingandfedconditions
AT wangyan singledoserandomizedcrossoverstudyinhealthychinesesubjectstoevaluatepharmacokineticsandbioequivalenceoftwocapsulesofcalciumdobesilate05gunderfastingandfedconditions
AT pengka singledoserandomizedcrossoverstudyinhealthychinesesubjectstoevaluatepharmacokineticsandbioequivalenceoftwocapsulesofcalciumdobesilate05gunderfastingandfedconditions
AT jiajingying singledoserandomizedcrossoverstudyinhealthychinesesubjectstoevaluatepharmacokineticsandbioequivalenceoftwocapsulesofcalciumdobesilate05gunderfastingandfedconditions